Gene-Guided weight loss: dopamine drug shows promise in obesity trial
NCT ID NCT03525002
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tested whether the drug bromocriptine, which boosts dopamine in the brain, can help people with obesity lose weight based on their FTO gene type. 120 adults with a BMI over 30 took either bromocriptine or a placebo for 18 weeks. The goal was to see if a specific gene variant (FTO rs8050136) predicts who will lose the most weight, aiming for a personalized treatment approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Cologne
Cologne, Germany
-
University Hospital Luebeck
Lübeck, Germany
-
University of Tuebingen, Department of Internal Medicine IV
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.